Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Bone Marrow Transplantation|November 26, 2008
Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCTK Masjosthusmann, K Ehlert, B R Eing, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 6, 2007
Piperacillin-tazobactam in pediatric cancer patients younger than 25 months: a retrospective multicenter surveyA Simon, T Lehrnbecher, U Bode, et al.
The Journal of Antimicrobial Chemotherapy|February 14, 1998
Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancerA H Groll, G Just-Nuebling, M Kurz, et al.
Antimicrobial Agents and Chemotherapy|October 3, 1999
Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbitsA H Groll, V Petraitis, R Petraitiene, et al.
The Journal of Infectious Diseases|July 7, 2000
Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous systemA H Groll, N Giri, V Petraitis, et al.
Antimicrobial Agents and Chemotherapy|November 16, 2001
Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbitsA H Groll, D Mickiene, V Petraitis, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|April 5, 2013
Fatal human metapneumovirus infection following allogeneic hematopoietic stem cell transplantationC Dokos, K Masjosthusmann, G Rellensmann, et al.
The Pediatric Infectious Disease Journal|August 26, 2000
Esophageal candidiasis in pediatric acquired immunodeficiency syndrome: clinical manifestations and risk factorsC C Chiou, A H Groll, C E Gonzalez, et al.
Antimicrobial Agents and Chemotherapy|September 15, 2001
Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma samplingA H Groll, D Mickiene, R Petraitiene, et al.
Antimicrobial Agents and Chemotherapy|February 22, 2001
Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemiaR Petraitiene, V Petraitis, A H Groll, et al.
Pageof 8